Recent Progress in the Application of Cyclopeptides Against Drug-Resistant Acinetobacter baumannii
Acinetobacter baumanniican is resistant to practically all antibiotics now on the market.It gains resistance by a variety of processes,including the expression of efflux pumps,modification of antimicrobial targets,and production of drug-inactivating enzymes.Currently,only a few drugs available to treat drug-resistant Acinetobacter baumannii,especially carbapenem-resistant Acinetobacter baumannii and multidrug-resistant Acinetobacter baumannii,and new resistant forms such as pan-resistant Acinetobacter baumannii are constantly emerging worldwide.Drug-resistant Acinetobacter baumannii has become one of the most challenging public health issues worldwide,creating an urgent need to develop new antibiotics.Cyclopeptides possess good stability,excellent receptor affinity,favorable cell membrane permeability as well as oral bioavailability,and the cyclopeptide agent datomycin has already been applied in clinics to treat infections caused by drug-resistant bacteria.Therefore,cyclopeptides have attracted widespread attention from scientists.In order to give theoretical support for the future discovery of new therapeutic candidates,this study will present an overview of the most recent research progress on cyclopeptides with antibacterial activity against drug-resistant Acinetobacter baumannii infections developed from 2020.
cyclopeptidesantibacterialdrug resistanceAcinetobacter baumanniimechanismsin vivo activity
NETL
NSTL
万方数据
